肾癌Fas表达异常与临床化疗药物作用机制的研究

目的探讨肾癌临床化疗药物对肾癌Fas蛋白表达影响及Fas蛋白表达异常在肾癌免疫逃避机制中的意义.方法采用免疫组织化学方法(VP法)检测44例肾癌标本和10例正常肾组织Fas蛋白表达;体外GRC-1肾癌细胞株与化疗药物5-氟尿嘧啶(5-FU)、阿霉素共同培养,流式细胞仪(FCM)检测肾癌细胞株的凋亡.结果肾癌组织Fas蛋白阳性表达率为22.8%,显著低于正常肾组织中的53.8%(P＜0.01);5-FU、阿霉素能增加GRC-1肾癌细胞株Fas表达并促进Fas单抗诱导的肾癌细胞的凋亡.结论肾癌通过Fas低表达逃避机体免疫攻击,化疗药物通过刺激肾癌Fas蛋白表达而促进肿瘤细胞的凋亡.

Study on Fas expression and the action of chemotherapeutic drugs in renal cell carcinoma

Objective To investigate the effect of clinical chemotherapeutic drugs on Fas antigen expression of renal cell carcinoma (RCC) and the relation between Fas expression and the immune escape mechanism of RCC. Methods The rates of Fas expression in 44 specimens of RCC and 10 of normal kidney tissue were determined by means of immunohistochemical technique. GRC-1 RCC cell line was cultured with the addition of 5-FU or adriamcin (ADR) and the GRC-1 RCC cell apoptosis was assayed by flow cytometry (FCM). Results The Fas positive rate in RCC (22.8%) was significantly lower than that in normal kidney tissue (53.8%, P <0.01).5-FU and ADR increased the Fas expression in GRC-1 RCC cell line and enhanced the apoptosis of GRC-1 cells induced by anti-Fas monoclonal antibody (CH11). Conclusion RCC can escape immunological recognition by lowering its Fas expression. Both 5-FU and ADR can promote the Fas expression and cell apoptosis in RCC.